	I.1. Consignor				I.2. IMSOC reference	I.2.a. Local reference			
	Name Address					I.3. Central Competent Authority			
	Country		ISO Code			I.4. Local Competent Authority			
Part I: Description of consignment	I.5. Consignee Name Address				I.6. Operator conducting assembly operations independently of an establishment Name				
sig	Country		ISO Code		Address Approval Number				
S					Country	ISO Code			
Jo uc	I.7. Country of orig	gin		ISO Code	I.9. Country of destination	ISO Code			
D	I.8. Region of origi	n		Code	I.10. Region of destination	Code			
scri	I.11. Place of dispa	ıtch			I.12. Place of destination				
B	Name Address				Name Address				
Ξ	Approval Number	r			Approval Number				
Par	Country		ISO Code		Country	ISO Code			
	I.13. Place of loadi	ng			I.14. Date and time of departure				
	Name Address								
	Approval Number	r							
	Country		ISO Code						
	I.15. Means of Tra				I.16. Transporter				
	Mode	International transport	Identification		Name				
		document			Address Activity ID				
					Country	ISO Code			
					I.17. Accompanying documents				
					Accompanying document				
					Date of issue				
					Country Place of issue				
	I.18. Transport con	nditions			11400 01 13500				
	Ambient 🗆		Chille	a 🗆	Frozen				
	I.19. Container No	/ Seal No							
	I.20. Certified as								
	Travelling circus/a	animal act 🛛	Quarantine or simi establishment 🗆		Organic fertilizers and soil improvers	Confined establishment \Box			
	Slaughter 🗆	—	Dispatch centre		Further processing	Registered equidae			
	Germinal product		Exhibition	1	Event or activity near borders 🗆 Ornamental aquaculture	Release into the wild 🗆 Other 🗆			
	Products for huma	an consumption	Further keeping 🗆		establishment 🗆	other 🗀			
	Relaying 🗆		Live aquatic animatic consumption \Box	als for human	Technical use 🗆				
	I.21. For transit th	rough a third coun	try						
	Third country				ISO Code				
	Exit point Entry point				BCP code BCP code				
		rough Member Sta	te(s)		I.23. For export				
	Member State	uon member da	ISO Code		Third country	LI ISO Code			
			130 couc		Exit point	BCP code			
	I.24. Estimated jou	-			I.25. Journey Log				
	I.27. Total quantity				I.28. Total gross weight				
	I.30. Description o	-							
	1. 01 LIVE ANIMA								
	0104 Live sheep and goats								

010420 Goats							
#1.	Commodity	Subcategory	Sex	Identification system			
Species		Identification Number	Age	Quantity			

INTRA

_	KOI LAN					establistilleri					
	II. Health info	ormation									
	I, the unde	rsigned offi	cial veterin	arian, hereb	by certify, tha	t:					
	II.1.	.The anima	als(1) in the consignment described in Part I meet the following requirements:								
		II.1.1.	Their confined establishment of dispatch is approved in accordance with Articles 97 and 99 of Regulation (EU) 2016/429.								
r al l II. Cel ull'autol		II.1.2.	listed in An examination	nnex of Com on, or wher 48 hour per	nmission Imp e this is not p						
מדרדי	II.2.	According health req	to official information, animals in the consignment described in Part I meet the following nirements:								
ÿ		II.2.1.	-		fined establis to be moved.	shment that is not subject to	movement restrictions				
	(2)(3) 🗆 either	[II.2.2.	(serotypes	1-24), wher	e no case of i	•	rus (serotypes 1-24) has beer				
			vaccinated 60 day per	l with a live riod before t	vaccine agai he date of mo	ns in the targeted animal pop nst infection with bluetongu ovement and the requirement Commission Delegated Reg	e virus (serotypes 1-24) in th nts laid down in Article				
	(2)(3) [II.2.2. They originate from a Member Sta and/or infection with bluetongue virus (se 32(1)(a), (b) or (c) or Article 32(2) o they					rotypes 1-24) and the requir	ements laid down in Article				
	(2) 🗆 either [II.2.2.1. have been kept in a Me						ly free from infection with h Article 40(3) of Commissio				
		(2)	🗆 either	[II.2.2.1.1.	for at least (50 days prior to the date of n	novement]]				
		(2)	□ and/or		for at least 2 subjected to samples col animal into	28 days prior to the date of n a serological test, with nega lected at least 28 days follow	novement and have been ative results, carried out on ring the entry date of the easonally free from infectior				
		(2)	□ and/or	[II.2.2.1.3.	subjected to collected at the Member	•	sults, carried out on samples entry date of the animal into				
	(2)	□ and/or	[II.2.2.2.	place of de			during transportation to the gainst attacks by vectors in a				
		(2)	🗆 either	[II.2.2.2.1.	for at least (60 days prior to the date of n	novement]] .				
		(2)	□ and/or	[II.2.2.2.2.	subjected to samples col	28 days prior to the date of n a serological test, with nega lected at least 28 days follow nent of the period of protect	tive results, carried out on ring the date of the				
		(2)	□ and/or	[II.2.2.2.3.	subjected to collected at	•	sults, carried out on samples late of the commencement o				
	(2)	□ and/or	[II.2.2.3.			gainst those serotypes from were reported during the p					

	II. Health info	ormation								
				State or zo	ne and are w	vithin the im	munity period g	uaranteed in the		
				specification	ons of the va	ccine and				
		(2)	🗆 either	[II.2.2.3.1.	have been v movement]		ore than 60 days	s before the date of	-	
Part II: Certification		(2)	□ and/or	[II.2.2.3.2.	PCR test, wi	ith negative i	results on sample	d vaccine and subj es collected at least e specifications of t	14 days	
rt II: Ceri	(2)	□ and/or	[II.2.2.4.	have been subjected with positive results to a serological test able to detect specific antibodies against all serotypes 1-24 of infection with bluetongue virus reported during the past 2 years in that Member State or zone and						
Pai		(2)	□ either	[II.2.2.4.1.	the serological test has been carried out on samples collected at least 60 days before the date of movement]]					
		(2)	□ and/or	[II.2.2.4.2.	2.4.2. the serological test has been carried out on samples collected at least 30 days before the date of the movement and the animal has been subjected to a PCR test, with negative results, carried out on samples collected not earlier than 14 days before the date of movement;]]]					
	(2)(3) 🗆 and/or	[II.2.2.	virus (sero bluetongu	otypes 1-24) e virus (serc	nor covered otypes 1-24) a	by the eradion of the the by the eradion of the by	cation programn	n infection with blu ne for infection wit wn in Article 32(1)(Ifilled, and they	h	
	(2)	□ either	[II.2.2.1.	have been protected against attacks by the vectors during transportation to the place of destination and have been kept protected against attacks by vectors in a vector protected establishment and						
		(2)	🗆 either	[II.2.2.1.1.	for at least	60 days prio	r to the date of m	novement]]		
		(2)	□ and/or	[II.2.2.1.2.	subjected to samples col	o a serologica llected at lea	al test, with nega st 28 days follow	novement and have tive results, carried ing the date of the ion against attacks	d out on	
		(2)	□ and/or	[II.2.2.1.3.	1.3. for at least 14 days prior to the date of movement and have been subjected to a PCR test, with negative results, carried out on samples collected at least 14 days following the date of the commencement o the period of protection against attacks by vectors;]]]				n samples	
	(2)	□ and/or	[II.2.2.2.	establishm centred on requireme	nent situated a the establish ents laid down	in a Membe hment, wher n in Sections	r State or in an a re surveillance in a 1 and 2 of Chap	o departure in an rea of at least 150 k compliance with t ter 1 of Part II of Ar d out during that p	he nnex V to	
		(2)	□ either	[II.2.2.2.1.	24 of infect the past 2 y place where	ion with blue ears in an ar e the animal	etongue virus wh ea of at least 150 s were kept and	st those serotypes f nich were reported) km radius centred are within the imm of the vaccine and	during l on the	
			(2)	🗆 either	[II.2.2.2.1.1.	have been v of moveme		than 60 days befor	e the date	
			(2)	□ and/or	[II.2.2.2.1.2.	have been v subjected to collected at	vaccinated with a of a PCR test, with	an inactivated vacc negative results on er the onset of the ne vaccine;]]]]	n samples	
		(2)	□ and/or	[II.2.2.2.2.	24 of infect the past 2 y	ion with blue ears in an ar	etongue virus wł	ist those serotypes nich were reported) km radius centred	during	

II. Booth information (2) • either [II.2.2.2.2.1. the animals have been subjected with positive results to a serological test carried out on samples collected at lease 50 days before the date of movement]] (2) • or [II.2.2.2.2.1. the animals have been subjected with positive results to a serological test carried out on samples collected at lease 30 days before the date of the movement and to a PCR test, with negative results, carried out on samples collected at lease 30 days before the date of the movement and the application of the analysis of the movement is and the subjected with positive results carried out on samples collected at lease 30 days before the date of movement and the date of movement and the set of origin authorised novement is antimals to another Member State of origin authorised novement is antimis to another Member State of control the Commission and the other Member State of action in factorial state state state. In the Member State of a control (EU) 2020(689 and the competent authority of the Member State of action is referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020(689 and (c)) (2) either III.2.2.1. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or III.2.2.1.4. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or III.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or III.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and <td< th=""><th>_</th><th>-</th><th>KOI LAN</th><th></th><th></th><th></th><th></th><th></th><th><u> </u></th></td<>	_	-	KOI LAN						<u> </u>
Image: Second			II. Health info	ormation					
1000000000000000000000000000000000000					(2)	∘ either	[II.2.2.2.2.1.	a serological test carried out on samples collected at lea	
(2) □ either [II.2.2.1.] with the status free from infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State state state submitted subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) □ either [II.2.2.1.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.1.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/689 and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/689 and (2) □ and/or [II.2.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State stat such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) □ and/or [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to	ertification	eruncation			(2)	0 or	[II.2.2.2.2.2.	a serological test carried out on samples collected at lea 30 days before the date of the movement and to a PCR test, with negative results, carried out on samples collected not earlier than 14 days before the date of	
the Member State of destination has informed the commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) either [II.2.2.1.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020(688 and the requirements Laid down in Article 33 of that Delegated Regulation are fulfilled.]]] (2) and/or [II.2.2.2.4) with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member States of destination has informed the Commission and the other Member States of destination has informed the Commission and the other Member States of destination has informed the Commission and the other Member States of Astat Such Novement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020(689 and (2) either [II.2.2.2.2] point 5 of Section		Part II: C		[II.2.2.	Part II of A State of or	nnex V to R	legulation (E	U) 2020/689 and the competent authority of the Member	
L Delegated Regulation, and (2) and/or [II.2.2.1.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member States that such movement is authorised subject to the conditions referred to in Article 32(2)(a), (b) and (c) of Delegated Regulation (EU) 2020(688 and (2) either [II.2.2.2. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and		the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/68							1
(2) and/or [II.2.2.1.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.1.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) either [II.2.2.2.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.3.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [(2)	□ either	[II.2.2.1.1.			
Part of the second s				(2)	□ and/or	[II.2.2.1.2.	-	-	
Delegated Regulation, and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) either [II.2.2.2.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation are fulfilled;]]] (2) and/or </td <th></th> <td></td> <td></td> <td>(2)</td> <td>□ and/or</td> <td>[II.2.2.1.3.</td> <td></td> <td></td> <td></td>				(2)	□ and/or	[II.2.2.1.3.			
32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.2. with an approved eradication program for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) either [II.2.2.2.1. point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.3. meither free from infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the o				(2)	□ and/or	[II.2.2.1.4.	-	-	
 (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised subject to the conditions referred to in Article 43(2)(a), (b) and (c) of Delegated Regulation (EU) 2020/689 and (2) □ either [II.2.2.2.1] point 5 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.2] point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.3] point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) □ and/or [II.2.2.2.4] point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) □ and/or [II.2.2.3] neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the other Member State stat such movement is authorised (2) □ either [II.2.2.3.] without any conditions, and (2) □ either [II.2.2.3.] without any conditions, and (2) □ and/or [II.2.3.2.] subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/688, and 							32(2) of Del	egated Regulation (EU) 2020/688 and the requirements	
Delegated Regulation, and (2) and/or [II.2.2.2.2. point 6 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.3. point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and (2) and/or [II.2.2.3.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.3.1. meither free from infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the other Member State of destination has informed the Commission and the other Member State of destination has informed the Commi	(2) □ and/or [II.2				[II.2.2.2.	(serotypes Commission subject to	1-24) and the ot the condition	e Member State of destination has informed the her Member States that such movement is authorised is referred to in Article 43(2)(a), (b) and (c) of Delegated	
Cancel and/or [II.2.2.3.] point 7 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and Cancel C				(2)	□ either	[II.2.2.2.1.			
 (2) and/or [II.2.2.2.4. point 8 of Section 1 of Chapter 2 of Part II of Annex V to that Delegated Regulation, and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.3. neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised (2) either [II.2.2.3.1. without any conditions, and (2) and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and 				(2)	\Box and/or	[II.2.2.2.2.			
 Delegated Regulation, and the requirements laid down in Article 32(1)(a), (b) or (c) or Article 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.3. neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised (2) either [II.2.2.3.1. without any conditions, and (2) and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and 				(2)	\Box and/or	[II.2.2.2.3.			
 32(2) of Delegated Regulation (EU) 2020/688 and the requirements laid down in Article 33 of that Delegated Regulation are fulfilled;]]] (2) and/or [II.2.2.3. neither free from infection with bluetongue virus (serotypes 1-24) nor covered by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised (2) either [II.2.2.3.1. without any conditions, and (2) and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and 				(2)	□ and/or	[II.2.2.2.4.	-	-	
 by the eradication programme for infection with bluetongue virus (serotypes 1-24) and the Member State of destination has informed the Commission and the other Member States that such movement is authorised (2) □ either [II.2.2.3.1. without any conditions, and (2) □ and/or [II.2.2.3.2. subject to the conditions referred to in point 5 of Section 1 of Chapter 2 of Part II of Annex V to Delegated Regulation (EU) 2020/689, and 							32(2) of Del	egated Regulation (EU) 2020/688 and the requirements	
(2)			(2)	□ and/or	[II.2.2.3.	by the erac 24) and the	dication prog e Member St	gramme for infection with bluetongue virus (serotypes 1 ate of destination has informed the Commission and the	l-
(2)				(2)	🗆 either	[II.2.2.3.1.	without any	y conditions, and	
							subject to th	he conditions referred to in point 5 of Section 1 of Chapt	er
				(2)	□ and/or	[II.2.2.3.3.			er

	II. Health info	rmation										
	n. nearth hno	Titlation										
					2 of Part II o	of Annex V to Delegated Re	egu	lation (EU) 2020/689, and				
	(2)					rred to in point 7 of Section 1 of Chapter gated Regulation (EU) 2020/689, and						
	2 of Part II of Annex V to						referred to in point 8 of Section 1 of Chapter Delegated Regulation (EU) 2020/689, and					
Part II: Certification					32(2) of Dele	nents laid down in Article egated Regulation (EU) 202 n Article 33 of that Delegat	20/6					
<mark>.</mark>	II.3	To the bes	t of my know	wledge and a	as declared b	y the operator:						
Part II		II.3.1.				spatch there are no abnor nimals to be moved.	ma	l mortalities with an				
		II.3.2.				nct with animals which are .1., or with animals of a low		-				
		II.3.3.										
	II.4.	-	ents are ma 1 (EU) 2020/6	-	ort the consig	gnment in accordance witl	h A	rticle 4 of Delegated				
	II.5.	animals, tł		10 days for				ansport by waterway/sea of nded by the duration of the				
	lumpy skir		compliance			n relation to emergency pr d Annex IX, Part 3, point (3		ective vaccination against), to Commission Delegated				
	skin diseas		iance with A			lation to emergency protec x IX, Part 3, point (3.2), to (ve vaccination against lumpy nmission Delegated				
	Animal we	lfare attesta	ation									
		ovisions of				h certificate were fit to be n the intended journey due						
	Notes:											
	In accordance with the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community, and in particular Article 5(4) of the Protocol on Ireland / Northern Ireland in conjunction with Annex 2 to that Protocol, references to European Union in this certificate include the United Kingdom in respect of Northern Ireland.											
	This animal health certificate shall be completed according to the notes for the completion of certificates provided for in Chapter 2 of Annex I to Commission Implementing Regulation (EU) 2020/2235.											
	Part I:											
	Box reference I.11:	"Place of dispatch": Indicate a confined establishment approved in accordance with Articles 97 and 99 of Regulation (EU) 2016/429.										
Box "Place of destination": Indicate a confined establishment approved in accordance with Articles 97 reference 99 of Regulation (EU) 2016/429. I.12:							dance with Articles 97 and					
	Part II:											
	(1)	There can	be one or m	nore animals	s in the consig	gnment.						
	(2)	Delete if n	ot applicabl	e.			(2) Delete if not applicable.					

	II. Health info	rmation		
	(3)	Only in case of animals belonging to the family Giraffidae, Moschidae or Tragulidae.	ies Antilocapridae, Bovidae, C	amelidae, Cervidae,
	Certifying Off	icer/Official veterinarian		
	Name (in capi	tal letters)	Qualification and title	
n	Date of signat Stamp	ure	Signature	
Part II: Certification	Stamp			
ũса				
rtif				
Ce				
t II:				
art				
H				